{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:49:09Z","timestamp":1783457349099,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008529","name":"Chiba University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008529","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008667","name":"SENSHIN Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H00184"],"award-info":[{"award-number":["21H00184"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02846"],"award-info":[{"award-number":["21H02846"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H05612"],"award-info":[{"award-number":["21H05612"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772044"],"award-info":[{"award-number":["81772044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.neuropharm.2022.109250","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T02:12:10Z","timestamp":1662689530000},"page":"109250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model"],"prefix":"10.1016","volume":"219","author":[{"given":"Li","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youge","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0439","authenticated-orcid":false,"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109250_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41380-019-0597-8","article-title":"MicroRNA mediators of early life stress vulnerability to depression and suicidal behavior","volume":"25","author":"Allen","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/mp.2013.196","article-title":"Integrating the roles of long and small non-coding RNA in brain function and disease","volume":"19","author":"Barry","year":"2014","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib4","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.biopsych.2015.04.022","article-title":"Ketamine as a prophylactic against stress-induced depressive-like behavior","volume":"79","author":"Brachman","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.cpr.2007.02.005","article-title":"Risk for recurrence in depression","volume":"27","author":"Burcusa","year":"2007","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109250_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109250_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainresbull.2022.02.004","article-title":"Brain\u2013gut -microbiota axis in depression: a historical overview and future directions","volume":"182","author":"Chang","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.109250_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajmg.b.32518","article-title":"miR-149 and miR-29c as candidates for bipolar disorder biomarkers","volume":"174","author":"Choi","year":"2017","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.neuropharm.2022.109250_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.clim.2016.06.002","article-title":"Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Beh\u00e7et's disease","volume":"169","author":"Coit","year":"2016","journal-title":"Clin. Immunol."},{"issue":"Suppl. 4","key":"10.1016\/j.neuropharm.2022.109250_bib11","first-page":"451","article-title":"MicroRNAs as candidates for bipolar disorder biomarkers","volume":"33","author":"Delalle","year":"2021","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.neuropharm.2022.109250_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib13","article-title":"Inflammation, lifestyle factors, and the microbiome-gut -brain axis: relevance to depression and antidepressant action","author":"Donoso","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109250_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109250_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.833259","article-title":"Ketamine as a prophylactic resilience-enhancing agent","volume":"13","author":"Evers","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib16","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109250_bib18","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.3390\/ijms23094555","article-title":"A new player in depression: miRNAs as modulators of altered synaptic plasticity","volume":"23","author":"Gao","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109250_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","article-title":"Regulation of microRNA function in animals","volume":"20","author":"Gebert","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2022.109250_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/ijms23010415","article-title":"A review on the role of miR-149 in the carcinogenesis","volume":"23","author":"Ghafouri-Fard","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109250_bib21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109250_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109250_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys","volume":"267","author":"Hashimoto","year":"2017","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109250_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109207","article-title":"A bibliometric analysis of research in (R)-ketamine from 2002 to 2021","volume":"218","author":"He","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109250_bib25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41398-021-01588-0","article-title":"miR-98-5p plays a critical role in depression and antidepressant effect of ketamine","volume":"11","author":"Huang","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109250_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: a tale of two enantiomers","volume":"35","author":"Jelen","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109250_bib27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109250_bib28","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.neuron.2022.05.027","article-title":"The role of hippocampal KCNQ2 channel in antidepressant actions of ketamine","volume":"110","author":"Ma","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109250_bib29","first-page":"27","article-title":"Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophylactic actions of (R)-ketamine. Transl","volume":"12","author":"Ma","year":"2022","journal-title":"Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109250_bib30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jad.2022.08.087","article-title":"Effects of spleen nerve denervation on depression-like phenotype, systemic inflammation, and abnormal composition of gut microbiota in mice after administration of lipopolysaccharide: a role of brain-spleen axis","volume":"317","author":"Ma","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109250_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41398-021-01379-7","article-title":"MicroRNA-dependent control of neuroplasticity in affective disorders","volume":"11","author":"Martins","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109250_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.112238","article-title":"Prophylactic (R,S)-ketamine selectively protects against inflammatory stressors","volume":"378","author":"Mastrodonato","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109250_bib33","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib34","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3390\/biomedicines9111659","article-title":"MicroRNAs as critical biomarkers of major depressive disorder: a comprehensive perspective","volume":"9","author":"Ortega","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuropharm.2022.109250_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16060-7","article-title":"Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model","volume":"7","author":"Qu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109250_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113633","article-title":"The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"418","author":"Rafa\u0142o-Uli\u0144ska","year":"2022","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109250_bib37","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/ijms23031294","article-title":"A systematic review of circulatory microRNAs in major depressive disorder: potential biomarkers for disease prognosis","volume":"23","author":"Rasheed","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109250_bib38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00296-013-2754-8","article-title":"The inflammatory circuitry of miR-149 as a pathological mechanism in osteoarthritis","volume":"34","author":"Santini","year":"2014","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.neuropharm.2022.109250_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114963","article-title":"Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers","volume":"198","author":"Scotton","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109250_bib40","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/gb-2011-12-6-r60","article-title":"Metagenomic biomarker discovery and explanation","volume":"12","author":"Segata","year":"2011","journal-title":"Genome Biol."},{"key":"10.1016\/j.neuropharm.2022.109250_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103569","article-title":"Non-coding RNAs in depression: promising diagnostic and therapeutic biomarkers","volume":"71","author":"Shi","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neuropharm.2022.109250_bib42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00406-016-0718-1","article-title":"Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression","volume":"267","author":"Shirayama","year":"2017","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109250_bib43","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109250_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pbb.2018.07.003","article-title":"Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine","volume":"172","author":"Tian","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109250_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0164-4","article-title":"Prefrontal cortex miR-29b-3p plays a key role in the antidepressant-like effect of ketamine in rats","volume":"50","author":"Wan","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.neuropharm.2022.109250_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109139","article-title":"Effects of (R)-ketamine on reduced bone mineral density in ovariectomized mice: a role of gut microbiota","volume":"213","author":"Wan","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109250_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153266","article-title":"MicroRNA-149: a review of its role in digestive system cancers","volume":"216","author":"Wang","year":"2020","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.neuropharm.2022.109250_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105635","article-title":"(R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: a role of gut-microbiota-brain axis","volume":"165","author":"Wang","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109250_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104762","article-title":"(R)-ketamine as preophylactic and therapeutic drug for neurological disorders: beyond depression","volume":"139","author":"Wang","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109250_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172870","article-title":"A historical review of antidepressant effects of ketamine and its enantiomers","volume":"190","author":"Wei","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109250_bib51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.brainresbull.2022.02.008","article-title":"Brain\u2013spleen axis in health and diseases: a review and future perspective","volume":"182","author":"Wei","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.109250_bib53","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12974-021-02356-z","article-title":"RhANP attenuates endotoxin-derived cognitive dysfunction through subdiaphragmatic vagus nerve-mediated gut microbiota-brain axis","volume":"18","author":"Wu","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2022.109250_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109250_bib55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psychres.2016.03.034","article-title":"Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine","volume":"239","author":"Yang","year":"2016","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109250_bib56","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib57","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41398-017-0031-4","article-title":"Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"7","author":"Yang","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109250_bib58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109250_bib60","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib61","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109250_bib62","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109250_bib63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","article-title":"An update on ketamine and its two enantiomers as rapid-acting antidepressants","volume":"19","author":"Zhang","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2022.109250_bib64","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109250_bib65","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41398-020-00878-3","article-title":"A key role of the subdiaphragmatic vagus nerve in the depression-like phenotype and abnormal composition of gut microbiota in mice after lipopolysaccharide administration","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109250_bib66","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00213-021-05889-6","article-title":"(R)-ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation","volume":"238","author":"Zhang","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109250_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109219","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109250_bib68","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jad.2021.02.063","article-title":"Emerging role of microRNAs in major depressive disorder and its implication on diagnosis and therapeutic response","volume":"286","author":"Zhou","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109250_bib69","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.3390\/ijerph17134710","article-title":"Assessment of ketamine and its enantiomers in an organophosphate-based rat model for features of Gulf War illness","volume":"17","author":"Zhu","year":"2020","journal-title":"Int. J. Environ. Res. Publ. Health"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:36Z","timestamp":1758439176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":69,"alternative-id":["S0028390822003094"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109250","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109250"}}